WINNIPEG, MANITOBA--(MARKET WIRE)--Jun 12, 2006 -- Medicure Inc. (TSX:MPH.TO - News)(AMEX:MCU - News), a cardiovascular drug discovery and development company, today announced that additional positive results from the Phase II MATCHED study were presented at the American Diabetes Association (ADA) Annual Scientific Session in Washington, DC. The study results demonstrated that MC-4232, a combination of MC-1 and the ACE Inhibitor, lisinopril (300mg/20mg) had a statistically significant 1.03mg/L (p equals 0.006) reduction in C-Reactive Protein (CRP) versus baseline. CRP is an important biomarker of inflammation, and is known to be highly predictive of cardiovascular risk. A reduction in CRP versus baseline was a predefined secondary endpoint of the MATCHED study.
